Refractory Lymphomas Recruiting Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Refractory Lymphoma

Indication	Status	Phase
DBCOND0042145 (Refractory Lymphomas)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Treatment	AZD-5363 (DB12218) Afatinib (DB08916) Binimetinib (DB11967) Crizotinib (DB08865) Dabrafenib (DB08912) Dasatinib (DB01254) Defactinib (DB12282) GSK-2636771 (DB11795) MK-1775 (DB11740) Nivolumab (DB09035) Osimertinib (DB09330) Palbociclib (DB09073) Pertuzumab (DB06366) Sapanisertib (DB11836) Sunitinib (DB01268) Taselisib (DB12108) Trametinib (DB08911) Trastuzumab (DB00072) Trastuzumab emtansine (DB05773) Vismodegib (DB08828)